Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

Fecha de publicación:

Autores organización

Autores

  • Rolfo C.
  • Cristofanilli M.
  • Paz-Ares L.
  • Diaz Mochon J.J.
  • Duran I.
  • Raez L.E.
  • Russo A.
  • Lorente J.A.
  • Malapelle U.
  • Gil-Bazo I.
  • Jantus-Lewintre E.
  • Pauwels P.
  • Mok T.
  • Serrano M.J.

Grupos de investigación

Resumen

Precision medicine was born with the development of new diagnostic techniques and targeted drugs, yielding better outcomes in cancer care. With the evolution and increasing sensitivity for detecting oncogenic drivers, liquid biopsies (LBs), specifically cell-free DNA (cfDNA) analysis, have been proposed as a minimally-invasive technique for genomic profiling. Ranging from sequencing techniques to PCR-based methods and other more complex strategies, this approach, currently applicable in some solid tumors with robust evidence, is showing promising opportunities in other cancers. However, difficulties in validating their clinical utility exist within limitation at different levels among several techniques, reporting of the results, lack of appropriate clinical trial designs, and unknown economic impact. One of the aims of the ISLB is to create recommendations to develop reliable and sustainable diagnostic, prognostic and predictive tools using LBs. This paper is addressing these objectives, helping the healthcare providers and scientific community to understand the potential of LB. © 2020 Elsevier B.V.

Datos de la publicación

ISSN/ISSNe:
1040-8428, 1879-0461

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY  Elsevier Ireland Ltd

Tipo:
Review
Páginas:
-
PubMed:
32428812
Enlace a otro recurso:
www.scopus.com

Citas Recibidas en Web of Science: 73

Citas Recibidas en Scopus: 87

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Biomarkers, Tumor; Cell-Free Nucleic Acids; Humans; Liquid Biopsy; Neoplasms; Precision Medicine; Societies, Medical; biological marker; cell free DNA; DNA; unclassified drug; cell free nucleic acid; tumor marker; breast cancer; cancer prognosis; cell free system; colorectal cancer; DNA determination; environmental sustainability; hematopoiesis; human; liquid biopsy; lung cancer; minimally invasive procedure; molecular dynamics; regulator gene; reliability; Review; solid malignant neoplasm; tumor cell; medical society; neoplasm; pathology; personalized medicine; procedures

Campos de Estudio

Financiación

Compartir la publicación